Breast cancer is a common malignant disease worldwide. Surgery, systemic therapy and radiotherapy, as the main treatment modalities, have significantly improved the prognosis of breast cancer[@b1]. Neoadjuvant endocrine therapy (NET), with the advantage of downsizing the tumor before surgery, provides a therapeutic alternative for patients with hormone receptor-positive (HR-positive), postmenopausal breast cancer[@b2]. Recently, many randomized clinical trials (RCTs) concerning NET have emerged and its clinical application is gradually gaining recognition. Based on the available research conclusions, more than 90% of experts voted for the use of NET in patients with HR-positive breast cancer during the 13th St. Gallen International Breast Cancer Conference[@b3]. Although some research results for NET have been reported, it is difficult to integrate information on the relative efficacy of all tested regimens because most individual trial compared only a few treatments; it is impossible to involve all therapeutic regimens in one trial[@b4]. Thus, a summary of these trials may be needed. Network meta-analysis not only synthesizes information from different trials and combines direct and indirect evidence on the relative effectiveness of the treatments, but also can tell us which regimen is appropriate after comparisons of the benefits and risks based on the evidence[@b5][@b6].

In this study, we assessed the efficacy and safety of NET systematically for postmenopausal, HR-positive, non-metastatic breast cancer by conducting direct and indirect comparisons from RCTs. We aimed to provide a useful summary of different treatment regimens that could be used to guide treatment decisions.

Results
=======

Overview of the Literature Search and Study Characteristics
-----------------------------------------------------------

A total of 998 articles were identified in the original database search, of which 973 were discarded after reviewing the titles and abstracts because they clearly did not meet the criteria for inclusion. The remaining full texts were read and six papers were excluded because they derived from two trials. Two papers were repetitive and one was reserved. Another eleven studies were discarded because six studies provided results from either a too small sample size or obviously inadequate information; the tumor size in one study was not assessed using calipers; only therapeutic effects of different dose of fulvestrant were reported in one study; two studies are still under way; and the last one was not a randomized trial. Finally, nine studies were identified and included ([Fig. 1](#f1){ref-type="fig"})[@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15].

The Assessment of the Risk of Bias
----------------------------------

The pooled risks of bias for the different studies included in this network analysis are presented in [Supplementary Figure 1](#S1){ref-type="supplementary-material"}.

Results of Direct Comparisons
-----------------------------

The nine studies comprised 2133 patients. The duration of treatment was from 12 to 24 weeks. An investigation into the optimal duration of exemestane was reported in one study[@b8]. To make a distinction, we defined exemestane (\<20wks) if the duration of exemestane was less than 20 weeks, and exemestane (≥20wks) if the treatment duration was than 20 weeks. There were three arms in two studies, respectively. One study was about anastrozole plus different treatment protocols of gefitinib compared with anastrozole, and we considered anastrozole versus anatrozole plus gifitinib[@b12]. As a result, ten arms were assessed including, chemotherapy, tamoxifen, letrozole, anastrozole, exemestane (≥20wks), exemestane (\<20wks), anastrozole plus tamxifen, letrozole plus everomilus, anatrozole plus gefitinib, and exemestane (\<20wks) plus celecoxib. All patients were postmenopausal women diagnosed with non-metastatic breast cancer. All patients except for four were HR-positive[@b15]. Four studies reported the levels of HER2[@b7][@b8][@b9][@b11]. Characteristics of the eligible studies are listed in [Table 1](#t1){ref-type="table"}.

The numbers of patients who achieved a clinical objective response (COR) and completed treatment were reported in nine studies. Eight studies provided information about fatigue and hot flushes, and seven studies reported the number of patients that received breast conserving surgery (BCS) after NET. Pathological complete response (pCR) was reported in four studies and only eight (1.1%) patients achieved pCR[@b8][@b11][@b15]. Direct comparisons were performed and are listed in [Table 2](#t2){ref-type="table"}. Forest plots are shown in [Supplementary Figures 2--6](#S1){ref-type="supplementary-material"}. From the eligible studies, a network diagram of the studies comparing COR was done using Stata, and the result are shown in [Fig. 2](#f2){ref-type="fig"}.

From direct comparisons, we found that the COR rate in the letrozole group was significantly higher than that in the tamoxifen group (odds ratio (OR): 2.20, 95% confidence interval (95%CI): 1.41 to 3.44, p = 0.001) or the exemestane (\<20wks) group (OR: 1.63, 95%CI: 1.01 to 2.64, p = 0.042). Significantly worse acceptability of letrozole was observed compared with letrozole plus everolimus (OR: 0.5, 95%CI: 0.28 to 0.87, p = 0.015); however, the incidence of fatigue in the letrozole group was remarkably lower than in the letrozole plus everolimus group (OR: 0.34, 95%CI: 0.13 to 0.89, p = 0.028). Besides, patients taking anastrozole suffered less fatigue than those taking tamoxifen (OR: 0.47, 95%CI: 0.22 to 0.98, p = 0.044). The incidence of hot flushes in the letrozole group was significantly higher than in the exemestane (\<20wks) (OR: 2.47, 95%CI: 1.30 to 4.70, p = 0.006), exemestane (\<20wks) plus celecoxib (OR: 8.44, 95%CI: 2.55 to 27.91, p = 0.0001) or chemotherapy (OR: 6.92, 95%CI: 1.29 to 37.29, p = 0.024) groups. More patients accepted BCS after taking anastrozole than among those taking tamoxifen (OR: 1.95, 95%CI: 1.26 to 3.02, p = 0.003) or letrozole (letrozole *vs*. anastrozole (OR: 0.39, 95%CI: 0.18 to 0.84, p = 0.016)).

Bayesian Network Meta-Analysis
------------------------------

To assess the consistency and inconsistency in the network meta-analysis, node-splitting analyses were performed. Which revealed no statistical differences between the direct and indirect evidence. From the eligible studies, indirect comparisons were then performed. The outcomes of indirect comparisons of COR, treatment completion (TC) and adverse events are shown in [Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}.

Network meta-analysis showed that everolimus plus letrozole more easily accepted by patients than exemestane (≥20wks) (OR: 856697.02, 95%CI: 1.88 to 87242934...), and exemestane (≥20wks) was also had worse acceptability than letrozole (OR: 0.00, 95%CI: 0.00 to 0.98). There was a statistically significant difference between letrozole and tamoxifen group in the comparison of COR (OR: 1.99, 95%CI: 1.04 to 3.80). In addition, the incidence of fatigue between the anastrozole plus gefitinib group and the everolimus plus letrozole group showed a significant difference (OR: 0.08, 95%CI: 0.01 to 0.83). The incidence of hot flushes in the exemestane (\<20wks) plus celecoxib group seem to be the lowest and four comparisons had statistically significant differences: anastrozole *vs*. exemestane (\<20wks) + celecoxib (OR: 8.44, 95%CI: 1.53 to 48.18), anastrozole + tamoxifen *vs*. exemestane (\<20wks) + celecoxib (OR: 13.11, 95%CI: 1.76 to 109.65), exemestane (\<20wks) + celecoxib *vs*. letrozole (OR: 0.11, 95%CI: 0.02 to 0.47), and exemestane (\>20wks) + celecoxib *vs*. tamoxifen (OR: 0.99, 95%CI: 0.02 to 0.52)). Furthermore, the incidence of hot flushes in the chemotherapy group was significantly lower than in another three treatment regimens (chemotherapy *vs*. letrozole (OR: 0.12, 95%CI: 0.01 to 0.76), chemotherapy *vs*. tamoxifen (OR: 0.11, 95%CI: 0.01 to 0.86), and anastrozole plus tamoxifen *vs*. chemotherapy (OR: 11.94, 95%CI: 1.14 to 171.80)).

Rankings for the outcomes of COR, TC, BCS and adverse events in the present analysis were also performed. The probabilities were calculated for a total of 100%, both within a rank over interventions and within an intervention over ranks. The top and second highest percentage within each intervention are shown in [Table 5](#t5){ref-type="table"}. Besides, a subgroup analysis was performed involving complete response (CR) and partial response (PR) ([Supplementary Figures 7--13](#S1){ref-type="supplementary-material"}).

Rankings showed that everolimus plus letrozole had the highest probability to rank first in the comparisons of COR (62%), PR (45%) and acceptability (44%). Seven studies reported information about the BCS rate. From the limited data, we found that more patients could accept BCS after receiving anastrozole plus gefitinib (69%).

Stochastic Multi-criteria Acceptability Analysis (SMAA)
-------------------------------------------------------

The SMAA benefit-risk analyses were based on evidence synthesis. The criteria were COR, TC, and the alternatives were treatment arms. Ranking for SMAA benefit-risk analysis is shown in [Supplementary Figure 14](#S1){ref-type="supplementary-material"}. The first and second high percentages within each intervention over ranks are shown in [Table 5](#t5){ref-type="table"}.

SMAA benefit-risk analyses suggested that everolimus plus letrozole, having a 64% possibility to rank first, was the best treatment arm when considering COR and TC, and letrozole was the second choice.

Discussion
==========

The use of neoadjuvant chemotherapy in the treatment of locally advanced breast cancer is well established. However, endocrine therapy, with lower toxicity, can be a valid alternative to chemotherapy in the treatment of hormone-sensitive tumors, particularly in postmenopausal women[@b16]. It can downsize tumors and provide an early measurement tool to evaluate response to endocrine therapy[@b3]. Here, we presented a meta-analysis of the efficacy of the available studies involving NET.

From the direct and indirect comparisons, we found that the letrozole group had a higher COR rate than the tamoxifen group. This was consistent with previous reports. For example, a study involving meta-analyses of two cohorts concerning adjuvant endocrine therapy demonstrated efficacy and superiority of aromatase inhibitors (AIs) when compared with tamoxifen[@b17][@b18]. In breast cancer, the PI3K/Ak/mTOR pathway is important in the clinical sensitivity of breast cancer to endocrine therapy. Everolimus, an mTOR inhibitor, can restore sensitivity to endocrine therapy[@b19]. A phase III randomized trial showed that everolimus combined with an AI could improve progression-free survival in patients with HR-positive, advanced breast cancer previously treated with non-steroidal AIs[@b20]. Ranking in this study also showed that everolimus plus letrozole might be the best choice for patients to reach COR and was more easily accepted.

In addition, we found that chemotherapy was the first choice for patients to obtain a CR. However, a phase 2 randomized trial of primary endocrine therapy versus chemotherapy did not show a significant difference for pCR (3% *vs*. 6%) and disease progression (9% *vs*. 9%) rates, respectively (p\>0.05). Besides, the rate of BCS was slightly higher in the endocrine group (33% *vs*. 24%; p = 0.058)[@b21]. The sample size in the chemotherapy arm was small and pCR was not analyzed in this study; therefore, more trials will be needed to compare NET with chemotherapy.

Compared with chemotherapy, an important superiority of endocrine therapy is its lower toxicity. In the nine included studies, severe adverse events were rarely reported and the most common side effects were fatigue and hot flushes. Although everolimus plus letrozole produced a higher incidence of fatigue, it was still more easily accepted. Ranking also showed that everolimus plus letrozole had the highest probability to rank first for acceptance. Hot flushes were another common side effect. This study suggested that anastrozole plus tamoxifen had a 57% probability to rank first and exemestane (\<20wks) plus celecoxib had a 47% probability to rank last. Therefore, when patients have severe hot flushes after receiving endocrine therapy, celecoxib, a non-steroidal anti-inflammatory drug (NSAID), is a good choice.

In this study, there was no significant difference between the exemestane (≥20wks) and exemestane (\<20wks) groups in terms of reaching COR and complete treatment. Ranking also struggled to decide which one was better than the other. In addition, adverse events in the original study investigating optimal duration of exemestane therapy were not available[@b8]. Thus, it was hard to produce a comprehensive analysis. SMAA suggested that exemestane (≥20wks) ranked last and exemestane (\<20wks) ranked sixth or seventh. A phase II study that investigated preoperative treatment with exemestane for 6 months in postmenopausal patients with HR-positive breast cancer showed a more beneficial effect for 6 months[@b22]. However, Hojo demonstrated that responses were equal during 4 or 6 months of exemestane treatment, and showed that 4-months of treatment with exemestane appeared to be warranted in postmenopausal patients because of its increased acceptability[@b8]. Therefore, the optimal duration of exemestane remains controversial.

This study provided an insight into the NET for HR-positive, postmenopausal breast cancer. However, it had some limitations. First, the number of studies and the patients included are relatively limited. Second, for the comparisons in the network meta-analysis, no direct evidence was available, and indirect comparisons might cause heterogeneity. Third, we did not consider the influence of diversity of ethnicity and the SMAA benefit-risk analysis only analyzed two criteria[@b23]. Finally, the indicator of this study is limited. The COR was restricted to being assessed using calipers, without considering other assessment methods, such as ultrasound and mammography. Therefore, future studies will be needed to assess more indicators and consider more influencing factors.

In conclusion, our study proved that letrozole plus everolimus is the most effective treatment for postmenopausal, HR-positive breast cancer in the neoadjuvant setting. In addition, when patients have hot flushes during the period of NET, NSAIDs, such as celecoxib, are recommended.

Methods
=======

Search Strategy
---------------

Studies were identified by searching Embase database, the Cochrane library and PubMed with the following search terms: breast cancer or breast neoplasm or breast carcinoma; neoadjuvant or preoperative; endocrine therapy or hormonal therapy. The searches were limited to studies written in English with full text. There was no date restriction. In addition, we screened the references of all studies fulfilling the eligibility criteria in case we missed some relevant articles by the electronic searches.

Selection Criteria
------------------

Randomized trials that compared at least two arms of different treatment regimens involving NET in postmenopausal patients with HR-positive, non-metastatic breast cancer were considered. There were no dose and duration restrictions. All titles and abstracts were screened to exclude obviously unmatched articles and the remaining full texts were read for further identification. If multiple publications of the same trial were retrieved, only the most informative publication was included. Risk of bias in the studies was assessed by two authors (Wang and Zhou) for quality; appropriateness of allocation, blinding, and management of incomplete outcome data; the completeness of reporting of outcomes and other bias using the Cochrane Collaboration risk of bias tool[@b24].

Data Extraction
---------------

A data extraction sheet based on Excel was developed. Data were extracted independently by two authors (Wang and Zhou) including: characteristics of trial participants (age, gender, menopausal status, HR and HER2 status, histological type, clinical tumor status, tumor grade and nodal status), the inclusion and exclusion criteria in each trial, type of intervention (type, dose, duration and frequency) and outcomes.

Definition of Outcomes
----------------------

The primary outcome in this study was the number of patients that achieved COR. COR included CR and PR. They were defined according to UICC, WHO or RECIST criteria. The tool used for tumor assessment in the studies was restricted to calipers. Other endpoints were the number of patients who completed treatment and the number of patients with adverse events. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (Version 2.0 or 3.0) with no grade restrictions. The adverse events concerned in this study were fatigue and hot flushes. The numbers of patients who reached pCR and received BCS were also considered.

Statistical Methods
-------------------

In the direct comparisons, OR was utilized for pooling effect sizes because most of the outcomes were dichotomous variables. If a direct comparison was based on two or more studies, statistical heterogeneity was calculated using the *I*^*2*^ statistic. Furthermore, we defined *I*^*2*^ above 50% as a large between-study heterogeneity. If there was no significant heterogeneity, data were pooled using the Mantel-Haenszel fixed effects model[@b25]. Results were reported with OR and 95%CI. All statistical tests were two-sided.

For comparisons between two interventions with both direct and indirect evidence, the consistency between these types of evidence was verified by the node-split analysis provided in the Aggregate Data Drug Information System (ADDIS), an open source evidence-based drug oriented strategy decision support system[@b26]. If there was no significant inconsistency, the relative effects of the interventions were analyzed using a consistency model based on a random-effects Bayesian model provided by the ADDIS software[@b27][@b28]. Benefit-risk analysis was performed using SMAA. The results of the analysis are presented as OR with 95% CI. Ranking for each treatment was performed by calculating the probability of each arm to achieve the best rank among all treatments. In addition, sensitivity analyses were considered.

Direct comparisons and risk of bias across studies were assessment by Stata, Version 11.2 (Stata Corp, College Station, TX, USA). Risk of bias in individual studies was assessed by Review Manager (RevMan), Version 5.3 (The Nordic Cochrane Centre: The Cochrane Collaboration, Copenhagen, Norway). Bayesian network meta-analyses and the node-splitting analyses were calculated by ADDIS,Version1.16.5. The reporting of this meta-analysis was done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[@b29].
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![Network diagram of studies comparing clinical objective response (COR) of different neoadjuvant endocrine therapy (NET) therapies for HR-positive breast cancer.\
Each link represents at least 1 study and the widths of each link are proportional to the number of studies comparing the particular arms. The size of each node is proportional to the total sample size. CT = chemotherapy, Ana = anastrozole, Tam = tamoxifen, Gef = gefitinib, Let = letrozole, Exe (\<20wks) = Exemestane (\<20wks), Exe (≥20wks) = Exemestane ((≥20wks), Cel = Celecoxib, Eve = Everolimus.](srep25615-f2){#f2}

###### Characteristics of the eligible studies.

  Author                     Year    Country            Clinical stage                    Arm          Duration (wks)   Num   Age (years), median (rang)   Postmenopausal (n)   HR+/HER2+(n)   Tumor grade (n)        Clinical tumor status (n)   Nodal status (n)                            
  ------------------------ -------- --------- ----------------------------------- ------------------- ---------------- ----- ---------------------------- -------------------- -------------- ----------------- ---- --------------------------- ------------------ ----- ---- ---- ---- ---- ----
  C.Palmieri                 2014      UK      T2/ above/any T with nodal ≥ 20mm          CT                 18         22                --                       22               22/2              0          15               4                      3           --    --   --   --   --   --
  Let                       18--23     22                     --                          22                22/2         1                14                       4                 3               --          --              --                      --          --    --                 
  Takashi Hojo               2013     Japan                IIA-IIIA                  Exe (\<20wks)           16         26           66 (51--80)                   26               26/1             --          --              --                      --          24    2    0    21   5    0
  Exe (≥20wks)                24       26                 64 (57--80)                     26                26/3        --                --                       --                --              24          2                0                      24           2    0                  
  Matthew J.Ellis            2011      US                  II or III                 Exe (\<20wks)         16--18       124          69 (43--90)                  124              124/8             35          69              20                      0           90    25   9    96   26   2
  Let                       16--18     127                65 (49--90)                     127              127/13       26                83                       1                 17              95          24               8                      80          41    6                  
  Ana                       16--18     123                65 51--87)                      123              123/12       30                73                       19                1               94          24               6                      01          29    3                  
  Jose´ Baselga              2009     Spain                   M0                        Eve+Let              16         138          69 (46--88)                  138              138/--            10          50              32                      46          100   29   9    84   38   9
  Let                         16       132                67 (43--84)                     132              132/--        8                55                       20                49              102         20              10                      84          36    6                  
  Louis Wing-Cheong Chow     2008     China                   NA                   Exe (\<20wks)+Cel         12         30           69 (49--87)                   30               30/6             --          --              --                      --          --    --   --   --   --   --
  Exe (\<20wks)               12       24                 67 (48--91)                     24                24/2        --                --                       --                --              --          --              --                      --          --    --                 
  Let                         12       28                 75 (49--93)                     28                28/2        --                --                       --                --              --          --              --                      --          --    --                 
  Ian E. Smith               2007      UK                   I-IIIB                      Ana+Gef              16         121               --                      121              121/--            23          55              14                      29          110   11   77   39   5     
  Ana                         16       85                    70.3                         85               85/--        18                33                       16                18              79          6               49                      35           1                       
  Luigi Cataliotti           2006     Italy                  LABC                         Ana                12         228           48.7--91.5                  228              228/--            --          --              --                      --          --    --   --   --   --   --
  Tam                         12       223                44.1--95.9                      223              223/--       --                --                       --                --              --          --              --                      --          --    --                 
  Ian E. Smith               2005      UK                    LABC                         Ana                12         113        73.2(51.8--90.2)               113              113/--            --          --              --                      --          --    --   --   --   --   --
  Tam                         12       108             71.5(49.8--88.4)                   108              108/--       --                --                       --                --              --          --              --                      --          --    --                 
  Ana+Tam                     12       109             73.2(51.6--85.7)                   109              109/--       --                --                       --                --              --          --              --                      --          --    --                 
  W.Eiermann                 2001    Germany             T2-T4c.N0-N2                     Let                16         154               68                      154              154/--                        --              --                      --          77    42   35   75   68   11
  Tam                         16       170                    67                          170              166/--       --                --                       --                --              91          30              49                      83          66    21                 

CT = chemotherapy, Ana = anastrozole, Tam = tamoxifen, Gef = gefitinib, Let = letrozole, Exe (\<20wks) = Exemestane (\<20wks), Exe (≥20wks)= Exemestane (≥20wks), Cel = Celecoxib, Eve = Everolimus.

###### Direct comparison for COR, TC, fatigue, hot flush and BCS.

                                          **Outcome**   **Events**   **Total**   **Events**   **Total**       **OR (95% CI)**
  -------------------------------------- ------------- ------------ ----------- ------------ ----------- --------------------------
  Let *vs*. Exe (\<20wks)                     COR          112          155          91          148      **1.63 (1.01 to 2.64)**
                                              TC           149          155         136          148        2.09 (0.79 to 5.54)
                                            Fatigue         14          155          11          148        1.23 (0.54 to 2.81)
                                           Hot flush        43          155          22          148      **2.47 (1.30 to 4.70)**
                                              BCS           11          127          17          124        0.60 (0.27 to 1.33)
  Let *vs*. Exe (\<20wks)+Cel                 COR           17          28           18          30         1.03 (0.36 to 2.95)
                                              TC            28          28           29          30         2.90 (0.11 to 74.13)
                                            Fatigue         4           28           3           30         1.50 (0.30 to 7.39)
                                           Hot flush        19          28           6           30       **8.44 (2.55 to 27.91)**
                                              BCS           --          --           --          --                  --
  Let *vs*. Let+Eve                           COR           78          132          94          138        0.68 (0.41 to 1.11)
                                              TC            90          132         112          138      **0.50 (0.28 to 0.87)**
                                            Fatigue         6           132          17          138      **0.34 (0.13 to 0.89)**
                                           Hot flush        22          132          15          138        1.64 (0.81 to 3.32)
                                              BCS           --          --           --          --                  --
  Let *vs*. CT                                COR           20          22           17          22         2.94 (0.50 to 17.14)
                                              TC            20          22           20          22         1.00 (0.13 to 7.81)
                                            Fatigue         10          22           7           22         1.79 (0.52 to 6.10)
                                           Hot flush        9           22           2           22       **6.92 (1.29 to 37.29)**
                                              BCS           4           22           1           22         4.67 (0.48 to 45.62)
  Let *vs*. Tam                               COR           85          154          61          170      **2.20 (1.41 to 3.44)**
                                              TC           153          154         169          170        0.91 (0.06 to 14.60)
                                            Fatigue         8           154          8           170        1.11 (0.41 to 3.03)
                                           Hot flush        31          154          41          170        0.79 (0.47 to 1.34)
                                              BCS           69          154          60          170        1.49 (0.95 to 2.33)
  Let *vs*. Ana                               COR           95          127          85          123        1.33 (0.76 to 2.31)
                                              TC           121          127         114          123         1.59(0.55 to 4.61)
                                            Fatigue         10          127          9           123        1.08 (0.42 to 2.76)
                                           Hot flush        24          127          18          123        1.36 (0.70 to 2.65)
                                              BCS           11          127          24          123      **0.39 (0.18 to 0.84)**
  Ana *vs*. Ana+Gef                           COR           48          79           52          109        1.70 (0.94 to 3.05)
                                              TC            74          85           95          121        1.84 (0.85 to 3.97)
                                            Fatigue         8           85           5           121        2.41 (0.76 to 7.64)
                                           Hot flush        11          85           7           121        2.42 (0.90 to 6.53)
                                              BCS           27          85           51          121        0.64 (0.36 to 1.14)
  Ana *vs*. Ana+Tam                           COR           42          113          43          109        0.91 (0.53 to 1.56)
                                              TC           106          113         100          109        1.36 (0.49 to 3.80)
                                            Fatigue         6           113          8           109        0.71 (0.24 to 2.11)
                                           Hot flush        20          113          30          109        0.57 (0.30 to 1.07)
                                              BCS           21          113          11          109        2.03 (0.93 to 4.45)
                                            Outcome       Events       Total       Events       Total           OR (95% CI)
  Ana *vs*. Tam                               COR          123          276          99          259        1.30 (0.92 to 1.83)
                                              TC           308          341         302          331        0.89 (0.53 to 1.51)
                                            Fatigue         11          341          22          331      **0.47 (0.22 to 0.98)**
                                           Hot flush        39          341          44          331        0.84 (0.53 to 1.33)
                                              BCS           82          255          45          228      **1.95 (1.26 to 3.02)**
  Ana *vs.* Exe (\<20wks)                     COR           85          123          78          124        1.32 (0.78 to 2.24)
                                              TC           114          123         114          124        1.11 (0.44 to 2.84)
                                            Fatigue         9           123          10          124        0.90 (0.35 to 2.30)
                                           Hot flush        18          123          10          124        1.95 (0.86 to 4.42)
                                              BCS           24          123          17          124        1.53 (0.77 to 3.01)
  Tam *vs*. Tam+Ana                           COR           39          108          43          109        0.87 (0.50 to 1.50)
                                              TC           101          108         100          109        1.30 (0.47 to 3.62)
                                            Fatigue         8           108          8           109        1.01 (0.36 to 2.80)
                                           Hot flush        28          108          30          109        0.92 (0.51 to 1.68)
                                              BCS           8           108          11          109        0.71 (0.27 to 1.85)
  Exe (\<20wks) *vs*. Exe (≥20wks)            COR           11          26           12          25         0.79 (0.26 to 2.40)
                                              TC            26          26           25          26         3.12 (0.12 to 80.12)
                                            Fatigue         --          26           --          25                  --
                                           Hot flush        --          26           --          25                  --
                                              BCS           4           26           1           25         4.36 (0.45 to 42.08)
  Exe (\<20wks) *vs*.Exe (\<20wks)+Cel        COR           13          24           18          30         0.79 (0.27 to 2.33)
                                              TC            22          24           29          30         0.38 (0.03 to 4.46)
                                            Fatigue         1           24           3           30         0.39 (0.04 to 4.02)
                                           Hot flush        12          24           6           30       **4.00 (1.20 to 13.28)**
                                              BCS           --          --           --          --                  --

CT = chemotherapy, Ana = anastrozole, Tam = tamoxifen, Gef = gefitinib, Let = letrozole, Exe(\<20wks) = Exemestane (\<20wks), Exe (≥20wks) = Exemestane (≥20wks), Cel = Celecoxib, Eve = Everolimus.

###### Indirect comparison of COR and TC.

![](srep25615-t3)

Light blue boxes represent clinical objective response (COR, 95%CI), gray boxes represent treatment completion (TC, 95%CI). ORs in light blue boxes represent the column-defining treatment compared with row-defining treatment, and ORs in gray boxes represent the row-defining treatment compared with column-defining treatment. For COR, ORs greater than 1 favor the column-defining treatment. For TC, ORs greater than 1 favor the row-defining treatment.

###### Indirect comparison of fatigue and hot flush.

![](srep25615-t3)

Light blue boxes represent clinical fatigue (95%CI), gray boxes represent hot flush (95%CI). ORs in the light blue boxes represent the column-defining treatment compared with row-defining treatment, and ORs in gray boxes represent the row-defining treatment compared with column-defining treatment. For Fatigue, ORs greater than 1 favor the row-defining treatment, indicating that the incidence of fatigue is lower. For hot flush, ORs greater than 1 favor the column-defining treatment, indicating that the incidence of hot flush is lower.

###### The first and second highest percentage within each intervention over ranks.

  **Rank**                **Ana**            **Ana+Gef**          **Ana+Tam**             **CT**            **Eve+Let**       **Exe (≥20wks)**    **Exe (\<20wks)**   **Exe (\<20wks)+Cel**        **Let**             **Tam**
  ---------------- --------------------- -------------------- -------------------- -------------------- ------------------- -------------------- ------------------- ----------------------- ------------------- --------------------
  COR               4,6(20%) **5(29%)**   **9(36%)** 10(22%)     5(16%) 6(16%)      9(10%) **10(58%)**   **1(62%)** 2(20%)     1(14%) 2(13%)      **7(23%)** 8(19%)       2(16%) 3(18%)       **2(35%)** 3(33%)   7(22%) **8(28%)**
  TC                 5(22%) **6(25%)**    8(22%) **9(36%)**      7(16%) 8(19%)        1(22%) 2(18%)      **1(44%)** 2(30%)   9(2%) **10(93%)**    7(19%) **8(22%)**       1(22%) 9(17%)       **3(34%)** 4(21%)     4(19%) 5(20%)
  PR                 **4(21%)** 5(20%)    8(18%) **9(34%)**      3(16%) 4(14%)      9(13%) **10(70%)**   **1(45%)** 2(18%)     8(15%) 9(14%)      6(19%) **7(22%)**       8(17%) 9(16%)       **3(25%)** 4(17%)   **6(20%)** 7(19%)
  CR                7,9(20%) **8(26%)**     4(15%) 3(18%)      9(18%) **10(34%)**    **1(94%)** 6(7%)    **4(20%)** 5(15%)     2(32%) 3(17%)        5(18%) 6(19%)       **2(34%)** 3(25%)     5(23%) **6(25%)**   **9(26%)** 10(23%)
  BCS                **2(52%)** 3(26%)    **1(69%)** 2(14%)      5(18%) 6(22%)      7(30%) **8(55%)**           --             7(36%) 8(40%)      **3(29%)** 4(20%)            --             **4(30%)** 5(28%)   5(29%) **6(37%)**
  Fatigue            6(22%) **7(26%)**    8(18%) **9(61%)**      2(19%) 3(15%)      **8(23%)** 9(18%)    **1(72%)** 2(14%)           --             6(19%) 7(21%)        2(18%) 3,4(11%)      3(23%) **4(26%)**   2(23%) **3(25%)**
  Hot flush          3(27%) **4(31%)**    6(20%) **7(32%)**    **1(57%)** 2(16%)      8(33%) 9(43%)      **5(31%)** 6(32%)           --           **6(41%)** 7(29%)     8(42%) **9(47%)**       3(26%) 4(29%)     **2(37%)** 3(25%)
  SMAA (COR, TC)     4(23%) **5(24%)**    8(22%) **9(26%)**        5--7(15%)          9(22%) 10(26%)     **1(64%)** 2(19%)   9(17%) **10(50%)**     6(18%) 7(20%)         2(16%) 3(17%)       **2(41%)** 3(31%)   6(19%) **7(22%)**

For fatigue and hot flush, rank 1 was worst and rank N was best. For others, rank 1 was best and rank N was worst. Bold figures represent the highest probabilities associated with the individual interventions and their associated ranks. Ana = anastrozole, Gef = gefitinib, Tam = tamoxifen, CT = chemotherapy, Eve = Everolimus, Let = letrozole, Exe (\<20wks) = Exemestane (\<20wks), Exe (≥20wks) = Exemestane (≥20wks), Cel = Celecoxib.

[^1]: These authors contributed equally to this work.
